AmpliChip CYP450 Test: personalized medicine has arrived in psychiatry

Abstract

The US FDA has granted market approval for the first pharmacogenetic test using a DNA microarray, the AmpliChip CYP450, which genotypes cytochrome P450 (CYP)2D6 and CYP2C19. The test uses software to predict phenotypes and tests for 27 CYP2D6 alleles, including the deletions and duplications, and three CYP2C19 alleles. Other DNA microarray platforms are being developed for CYP testing, but none have been completely developed or approved by the FDA to date. The differences between an implementation of pharmacogenetic tests centered on the individual and implementation using a public health approach are discussed. In this review, the major obstacles to the wide implementation of pharmacogenetic testing in the clinical environment are summarized.

Keywords::

• AmpliChip CYP450 Test
• antidepressant
• antipsychotic
• CYP2C19
• CYP2D6
• DNA microarray
• genotyping
• pharmacogenetics
• pharmacokinetics
• psychiatry